Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive ...

Background/aims Although 0.01% atropine is widely used for myopia control, its efficacy is debated and its effectiveness ...

STAR randomized 847 US/European patients (3–14 years; -0.50 to -6.00 D) 1:1:1 and demonstrated primary endpoint success at 36 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Three studies showed that adults aged 20 to 50 years ...

Please provide your email address to receive an email when new articles are posted on . Bell reported results from the phase 3 CHAMP clinical study, which evaluated children with –0.5 D to –6 D ...

Prior to this approval, the only other device indicated for slowing pediatric myopia progression was a contact lens. The Food and Drug Administration (FDA) has cleared the Essilor Stellest eyeglass ...

According to a secondary analysis of the 24- Month Myopia Outcome Study of Atropine in Children (MOSAIC) trial, 0.05% atropine eye drops were more effective in controlling myopia progression and axial ...

Add Yahoo as a preferred source to see more of our stories on Google. In late September the U.S. Food and Drug Administration made an announcement that has the potential to positively impact tens of ...

Child eye test and eye exam. Little girl having eye check-up, with phoropter. Doctor performs eye test for child. This story is part of a series on the current progression in Regenerative Medicine.

An increase in myopia progression was observed among Chicago-area children early in the COVID-19 pandemic, reported researchers, who suggested that closure of schools and cancelling of activities may ...

In September 2025, a first-of-its-kind medical device — glasses — to prevent pediatric myopia was granted marketing authorization by the FDA. In a 2-year randomized controlled trial, the Essilor ...

Children and adolescents were at higher risk for myopic maculopathy progression if they had worse best-corrected visual acuity and longer axial length, among other risk factors. Myopic maculopathy ...